LncRNA MCF2L-AS1 inhibits neuronal damage induced by 1-methyl-4-phenylpyridinium (MPP+) via regulating miR-28-5p.

Abstract

Parkinson's disease (PD) is the second most prevalent progressive neurological movement condition worldwide. Previous studies have reported aberrant expression of lncRNA MCF2L-AS1 in PD. Therefore, this study aims to investigate the clinical significance of MCF2L-AS1 in PD patients and to explore whether MCF2L-AS1 is involved in the disease progression of PD by regulating miR-28-5p expression. The expression of MCF2L-AS1 was detected by using RT-qPCR. The diagnostic function of MCF2L-AS1 in PD was analyzed via ROC curves. CCK-8 assay was used to measure cell viability, and the apoptosis rate and ROS level were detected by flow cytometry. The targeted binding relationship between MCF2L-AS1 and miR-28-5p was detected using a dual-luciferase reporter gene assay. The concentration of MDA, SOD, and proinflammatory factors (TNF-α, IL-1β, and IL-6) was detected by using ELISA kits. This study found that the expression of MCF2L-AS1 was downregulated in patients with PD, and MCF2L-AS1 had predictive potential in PD. In addition, MCF2L-AS1 regulated MPP⁺-induced cell viability, apoptosis, oxidative stress, and inflammation of SH-SY5Y cells by regulating miR-28-5p expression. Therefore, MCF2L-AS1 may function as a biomarker for the diagnosis and treatment of PD.